Befunolol (INN) is a beta blocker with intrinsic sympathomimetic activity used in the management of open-angle glaucoma.[1] It also acts as a β adrenoreceptor partial agonist.[2][3] Befunolol was introduced in Japan in 1983 by Kakenyaku Kako Co. under the trade name Bentos.[4]

References

  1. ^ Reichl S, Müller-Goymann CC (January 2003). "The use of a porcine organotypic cornea construct for permeation studies from formulations containing befunolol hydrochloride". International Journal of Pharmaceutics. 250 (1): 191–201. doi:10.1016/S0378-5173(02)00541-0. PMID 12480285.
  2. ^ Koike K, Takayanagi I (October 1986). "A beta-adrenergic partial agonist (befunolol) discriminates two different affinity sites". Japanese Journal of Pharmacology. 42 (2): 325–8. doi:10.1254/jjp.42.325. PMID 2879061.
  3. ^ Takayanagi I, Koike K (January 1985). "A beta-adrenoceptor blocking agent, befunolol as a partial agonist in isolated organs". General Pharmacology. 16 (3): 265–7. doi:10.1016/0306-3623(85)90080-1. PMID 2862092.
  4. ^ Pharmaceutical Manufacturing Encyclopedia (3rd revised ed.). Norwich, N.Y.: William Andrew Publishing. January 14, 2008. p. 542. ISBN 978-0815515265.